Our Team

Our studio was forged in 2021 by – Max, Michel, and Sriram – united by their shared goal to re-establish discovery as the basis for the next generation of immunotherapies.

With their deep knowledge of immunobiology and their impressive track record of discovering and developing multiple, multibillion-dollar immunotherapies, they have positioned Foundery to increase the efficiency and effectiveness of the pre-clinical R&D process.

They aim to preserve the innovative culture of biotech and bridge the translational gap by providing leading academic scientists with exclusive access to best-in-class technology platforms and the necessary R&D infrastructure to transform their discoveries into breakthrough therapies.

Executive Management Team

A proven record of selecting and developing commercially successful therapies

Max Krummel, PhD

Founder & Managing Member
  • UCSF Professor & Endowed Chair in Experimental Pathology
  • Discovered and patented Checkpoint Blockade Target CTLA-4 (2022 Yervoy® Sales: $2B)
  • Defined Myeloid Tuning & founded Pionyr (secured $1.7B Buyout Option from Gilead in 2020)
  • Discovered Immune Archetypes in Cancer & COVID
  • PhD, University California, Berkeley
View full bio

Michel Streuli, PhD

Founder, Managing Member, & Chief Executive Officer
  • Drove early development of multiple immunotherapies, including IntronA and Keytruda® (2022 Keytruda® Sales: $21B)
  • 20+ year biotech veteran
  • Former Professor at Harvard and Dana-Farber Cancer Institute
  • PhD, University of Zurich
View full bio

Venkataraman “Sriram”, PhD

Founder, Managing Member, & Chief Scientific Officer
  • Guided preclinical pharmacology for Keytruda® and led Pionyr’s non-clinical PY314 program
  • 15+ years experience in immuno-oncology R&D and strategy development at Schering-Plough, Merck, Gilead and Pionyr
  • Expertise in small molecule and biologics development for immuno-oncology
  • PhD, University of Madras
View full bio

Jate Sam, MBA, CLP

Chief Business Officer
  • Executed >$10B in M&A, financing, licensing transactions and ~$70M in PE/VC investments
  • 20 years of investment banking, corporate development, principal investing and general management experience in the biopharma and consumer sectors
  • MBA, Kellogg School of Management, Northwestern University
  • Certified Licensing Professional
View full bio

Operating Team and Studio

Team’s deep experience enables translation of academic discoveries into high-value preclinical therapies

Elizabeth Edmiston, PhD

Senior Director, Business Operations & Investor Relations
  • 7 Years Academic and Industry Experience
  • Prior Position: Senior Alliance and Business Development Manager, UCSF
  • PhD, Immunology, University of California, Davis
View full bio
LinkedIn

Joshua Pollack, MS

Senior Director, Bioinformatics
  • 14 Years Academic and Industry Experience
  • Prior Position: Associate Director, Bioinformatics & Trans. Biology, Pionyr
  • MS, Computational Biology and Genomics, University of California, Berkeley
View full bio
LinkedIn

Vladi Juric, PhD

Senior Director of Biology and Pharmacology
  • 13 Years Academic and Industry Experience
  • Prior Position: Director, Early Discovery Biology, Pionyr
  • PhD, Biochemistry and Molecular Genetics, University of Illinois, Chicago
View full bio
LinkedIn
Map of the Foundery headquarters near the UCSF campus

Foundery Headquarters

  • Our 350 Parnassus location provides unprecedented physical proximity to cutting-edge immunologists
  • 13,600 square feet of laboratory and office space
  • Designed to accommodate a 1-2 NewCos

Scientific Advisors

A complementary amalgam of cutting-edge scientists with expertise in basic, clinical, and applied immunology

Adil Daud, MD

Director of Melanoma Clinical Research, HDFCCC, UC San Francisco
Immunotherapy KOL
View full bio

Ananda Goldrath, PhD

Executive Vice President, Allen Institute for Immunology
Immune Memory KOL
View full bio

Dan Littman, MD, PhD

Helen L. and Martin S. Kimmel Professor of Molecular Immunology, NYU School of Medicine
Integrated Immune KOL
View full bio

Richard Locksley, MD

Marion and Herbert Sandler Distinguished Professor, UC San Francisco
Innate Lymphocyte Biology KOL
View full bio

Leonard G. Presta, PhD

Retired Biotech Veteran
Renowned Antibody & Protein Engineer
View full bio

Alexis Combes, PhD

Associate Professor, Pathology, UC San Francisco
Immune Archetype KOL
View full bio

Business Advisors

Seasoned executives with significant venture, operating, M&A and business development experience

Pete Briger, MBA

Executive Chairman, Fortress Investment Group
View full bio

Jeff Brody, MBA

Managing Member Emeritus & Co-Founder, Redpoint Ventures
View full bio

Rekha Hemrajani, MBA

Board Member, ALX Oncology | Bioage | MaxCyte
View full bio

Forrest Metz, PhD, M. Phil

Founder and Managing Director, Dev Equity
View full bio

Saira Ramasastry, MS, M. Phil

Founder and Managing Partner, Life Sciences Advisory
View full bio

Wendy Petka, PhD, JD

Vice President, IP, Horizon Therapeutics
View full bio

Contact Us

Interested in learning more? We're looking forward to hearing from you.

GET IN TOUCH